An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

Multiple myeloma involves a comprehensive approach that combines blood tests, imaging, and bone marrow studies. Learn about ...

New criteria make high-risk smoldering multiple myeloma treatable, opening door to future 'chronic' disease status ...

This case highlights the need for immunohistochemical profiling of patients with multiple breast nodules and a history of refractory myeloma.

251929 Introduction: Multiple myeloma is a malignant proliferation of plasma cells which may accumulate in the skeleton causing lytic bone lesions or in the soft tissues (extramedullary disease).

One in 10 progressed solely with bone lesions, highlighting the importance of early detection. HealthDay News — Annual whole-body, low-dose computed tomography (WBLDCT) can improve the ...

The researchers found that 36.3% of participants progressed to symptomatic multiple myeloma. Nearly one in 10 with progression (9.7%) progressed solely with bone lesions.

Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow (the soft, inner parts of certain bones where new blood cells are made). They are an important part of ...

In fact, all people with multiple myeloma will have a relapse or become resistant to treatment at some point.1 Recent data from newly diagnosed patients show that about 10% of those starting a novel ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

The incurable bone marrow cancer “multiple myeloma” often develops unnoticed in the bone marrow over decades. In advanced stages, lesions form that can destroy the bone and spread to other ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.